We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for real-time alerts, custom portfolio, and market movers
| Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
|---|---|---|---|---|---|
| Haleon | LSE:HLN | London | Ordinary Share | GB00BMX86B70 | ORD GBP0.01 |
| Price Change | % Change | Share Price | Shares Traded | Last Trade
|
|
|---|---|---|---|---|---|
| 4.80 | 1.28% | 379.00 | 48,622,543 | 16:29:59 |
| Bid Price | Offer Price | High Price | Low Price | Open Price | |
|---|---|---|---|---|---|
| 379.00 | 379.10 | 379.70 | 373.40 | 373.40 | |
| Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
|---|---|---|---|---|---|
| Offices-holdng Companies,nec | 11.3B | 1.05B | 0.1148 | 33.01 | 34.18B |
| Last Trade Time | Trade Type | Trade Size | Trade Price | Currency |
|---|---|---|---|---|
| 17:00:54 | O | 5,443,438 | 373.40 | GBX |
| Date | Time | Source | Headline |
|---|---|---|---|
| 11/12/2024 | 16:00 | UK RNS | Haleon PLC Holding(s) in Company |
| 11/12/2024 | 12:45 | UK RNS | Haleon PLC Director/PDMR Shareholding |
| 10/12/2024 | 14:15 | UK RNS | Haleon PLC Holding(s) in Company |
| 05/12/2024 | 10:54 | ALNC |  IN BRIEF: Haleon says Pfizer representative steps down from board |
| 05/12/2024 | 10:00 | UK RNS | Haleon PLC Board Changes |
| 28/11/2024 | 14:30 | UK RNS | Haleon PLC Holding(s) in Company |
| 27/11/2024 | 16:00 | UK RNS | Haleon PLC Holding(s) in Company |
| 26/11/2024 | 15:00 | UK RNS | Haleon PLC Holding(s) in Company |
| 22/11/2024 | 16:00 | UK RNS | Haleon PLC Director/PDMR Shareholding |
| 22/11/2024 | 15:30 | UK RNS | Haleon PLC Holding(s) in Company |
Haleon (HLN) Share Charts1 Year Haleon Chart |
|
1 Month Haleon Chart |
Intraday Haleon Chart |
| Trade Time | Trade Price | Trade Size | Trade Value | Trade Type |
|---|---|---|---|---|
| 2024-12-11 18:50:16 | 373.40 | 5,443,438 | 20,325,797.49 | O |
| 2024-12-11 18:49:36 | 373.40 | 5,443,438 | 20,325,797.49 | O |
| 2024-12-11 17:15:00 | 373.40 | 8,758,000 | 32,702,372.00 | O |
| 2024-12-11 17:15:00 | 373.40 | 8,758,000 | 32,702,372.00 | O |
| 2024-12-11 16:51:45 | 379.00 | 43,628 | 165,350.12 | O |
| Top Posts |
|---|
Posted at 11/12/2024 08:20 by Haleon Daily Update Haleon is listed in the Offices-holdng Companies,nec sector of the London Stock Exchange with ticker HLN. The last closing price for Haleon was 374.20p.Haleon currently has 9,133,887,197 shares in issue. The market capitalisation of Haleon is £34,617,432,477. Haleon has a price to earnings ratio (PE ratio) of 33.01. This morning HLN shares opened at 373.40p |
Posted at 14/11/2024 10:20 by laurence llewelyn binliner #Anhar, a slow and steady growth share IMO, as the debt winds off dividends will increase, hopefully somewhere closer to the GSK 4% payout..02.08.2023 - net debt at 30.06.2023 of GBP9,5BN with 3.4x net debt/adjusted EBITDA 29.02.2024 - net debt at 31.12.2023 of GBP8.5BN with 3.0x net debt/adjusted EBITDA 01.08.2024 - net debt at 30.06.2024 of GBP8.4BN with 2.9x net debt/adjusted EBITDA 31.10.2024 - target net debt/adjusted EBITDA of around 2.5x |
Posted at 14/11/2024 09:56 by anhar As an income investor I won't be adding at the current very low yield. Even a big rise in the divis of say 50% would still leave the yield too low for me to increase my holding with the share price around the present level. For most purchases, either top-ups or new holdings, I like to target a yield of at least 5% in current market conditions though I sometimes make exceptions to this for portfolio and diversification reasons.I continue though to retain my holding from the GSK demerger as I think HLN has decent potential divi growth and my favoured approach is to to nothing. |
Posted at 06/11/2024 09:27 by anhar No reasons, share prices mostly move randomly. |
Posted at 05/11/2024 11:02 by philanderer Berenberg: Haleon on road to growthHaleon (HLN), the consumer health group spun out of GSK, is en route to a more ‘balanced growth algorithm’, says Berenberg. Analyst Bethan Davies retained her ‘buy’ recommendation and increased the target price marginally from 454p to 456p on the Citywire Elite Companies A-rated owner of brands such as Sensodyne and Panadol, which softened 0.2% to 371.4p yesterday, but is and is up 17% since listing in 2022. Davies said catalysts for the stock price were becoming ‘increasingly visible’ and she is expecting volume growth to accelerate in the fourth quarter to 3.6% from 2.8% in the third quarter. Erectile dysfunction drug Eroxon has also been launched in the US and she expects this to contribute to organic sales growth next year. On top of this, management is planning a capital markets day in the first half of next year, ‘which we expect will remind investors of the structural growth opportunities within Haleon’s core categories’. ‘We continue to see an additional optionality from a post-overhang re-rating as Pfizer continues to sell down its stake in Haleon,’ she said. citywire.com |
Posted at 08/10/2024 10:02 by philanderer UBS raises Haleon price target to 445 (410) pence - 'buy'Deutsche Bank raises Haleon price target to 375 (340) pence - 'hold' Barclays cuts Haleon price target to 406 (407) pence - 'overweight' |
Posted at 01/10/2024 09:27 by philanderer (Alliance News) - Pfizer Inc sold a 7.6% stake in consumer health products firm Haleon PLC for GBP2.7 billion, the investment banks running the offer confirmed on Tuesday.Pfizer, a New York-based pharmaceuticals firm, sold 640 million Haleon shares at 380 pence per share in a placing run by Goldman Sachs International and BofA Securities as joint global coordinators. Haleon bought back an additional 60.5 million shares from Pfizer at the same price. As a result, Pfizer's stake in Haleon has been reduced to 15.0% from 22.6%. |
Posted at 25/9/2024 11:03 by anhar Yes they have. As you say HLN has shown high growth, in my case against my personal demerger tax base cost of about 249p. That figure will vary for everyone as it depends on their original cost of old GSK.But as I've said I'm only in shares for the divis and as such have been running an income port for decades, not for capital gains, though the latter are of course welcome. I hold very long term in most cases and will definitely be retaining my HLN stock. |
Posted at 24/9/2024 09:58 by anhar I'd add bid potential to the reasons for the high rating. There was already an abortive bid from Unilever just prior to the GSK demerger so I expect many people think that HLN may be taken out at some stage.I retained my demerger HLN shares which have shown excellent growth, driving up the rating, though I'm just an income investor and it has demonstrated decent divi growth over its short independent existence. |
Posted at 10/9/2024 13:02 by mattboxy Hopefully that will firm up the share price! |
Posted at 19/5/2024 09:04 by philanderer Yes, I would have thought so. This from early april.Haleon overhang can be gone in a year, suggests Barclays One of the biggest drags on the share price of consumer group Haleon might be gone by the end of the year suggests Barclays. According to the broker, and based on Pfizer's latest placing, it's possible it and GSK will have entirely sold down by the end of this year, leaving Haleon 100% free float, said the broker. “Given repeated investor feedback about the overhang being a barrier to share price performance, we think this could be a significantly helpful potential catalyst.” Currently, Pfizer has 2062m shares in Haleon (22.6%) and GSK has 385m (4.2%) for a total overhang of 27%, down from 45% in May 2023 before the first GSK placing. “The pace of sell-down is accelerating and our analysis shows Haleon could be overhang-free by year-end at the current rate of progress,” said the broker. “With a 90-day lockup from the Mar24 placing, there is time for three more placings before year-end, assuming the lockup remains unchanged. “Haleon also has £185m remaining in its announced buyback plans for this year, which is 57m shares at the current share price. This would leave an overhang of 18m shares, or 0.2% of Haleon, less than a rounding error.” Barclays sees the overhang as a key reason for Haleon’s strong sales performance since its split from GSK has failed to translate into a better share price performance. “When Haleon spun in summer 2022 there was considerable scepticism about its 4-6% organic sales growth target, yet that year it delivered 9%. “Then there was considerable scepticism about it delivering 4-6% in 2023 given the 9% comp, yet last year it delivered 8%. Barclays added that Haleon remains one of its most preferred names within European Consumer Staples, a sector it sees as highly attractive, and potentially consolidating. The broker has a price target of 390p for Haleon and an overweight rating. proactiveinvestors.c |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
